These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 26467273)

  • 41. An image guided treatment platform for prostate cancer photodynamic therapy.
    Betrouni N; Colin P; Puech P; Villers A; Mordon S
    Annu Int Conf IEEE Eng Med Biol Soc; 2013; 2013():370-3. PubMed ID: 24109701
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Techniques for delivery and monitoring of TOOKAD (WST09)-mediated photodynamic therapy of the prostate: clinical experience and practicalities.
    Weersink RA; Bogaards A; Gertner M; Davidson SR; Zhang K; Netchev G; Trachtenberg J; Wilson BC
    J Photochem Photobiol B; 2005 Jun; 79(3):211-22. PubMed ID: 15896648
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Photodynamic therapy in colorectal cancer treatment: the state of the art in clinical trials.
    Kawczyk-Krupka A; Bugaj AM; Latos W; Zaremba K; Wawrzyniec K; Sieroń A
    Photodiagnosis Photodyn Ther; 2015 Sep; 12(3):545-53. PubMed ID: 25930668
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Vascular targeted photodynamic therapy with palladium-bacteriopheophorbide photosensitizer for recurrent prostate cancer following definitive radiation therapy: assessment of safety and treatment response.
    Trachtenberg J; Bogaards A; Weersink RA; Haider MA; Evans A; McCluskey SA; Scherz A; Gertner MR; Yue C; Appu S; Aprikian A; Savard J; Wilson BC; Elhilali M
    J Urol; 2007 Nov; 178(5):1974-9; discussion 1979. PubMed ID: 17869307
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Preclinical study of the novel vascular occluding agent, WST11, for photodynamic therapy of the canine prostate.
    Chevalier S; Anidjar M; Scarlata E; Hamel L; Scherz A; Ficheux H; Borenstein N; Fiette L; Elhilali M
    J Urol; 2011 Jul; 186(1):302-9. PubMed ID: 21600602
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Photodynamic therapy for focal ablation of the prostate.
    Arumainayagam N; Moore CM; Ahmed HU; Emberton M
    World J Urol; 2010 Oct; 28(5):571-6. PubMed ID: 20454966
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Photodynamic therapy in colorectal cancer treatment--The state of the art in preclinical research.
    Kawczyk-Krupka A; Bugaj AM; Latos W; Zaremba K; Wawrzyniec K; Kucharzewski M; Sieroń A
    Photodiagnosis Photodyn Ther; 2016 Mar; 13():158-174. PubMed ID: 26238625
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Vascular targeted photodynamic therapy for localized prostate cancer.
    Lepor H
    Rev Urol; 2008; 10(4):254-61. PubMed ID: 19145269
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Photosensitizers in prostate cancer therapy.
    Gheewala T; Skwor T; Munirathinam G
    Oncotarget; 2017 May; 8(18):30524-30538. PubMed ID: 28430624
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A model to estimate the outcome of prostate cancer photodynamic therapy with TOOKAD Soluble WST11.
    Betrouni N; Lopes R; Puech P; Colin P; Mordon S
    Phys Med Biol; 2011 Aug; 56(15):4771-83. PubMed ID: 21753234
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Decision Regret and Quality of Life after Focal Therapy with Vascular-Targeted Photodynamic Therapy (TOOKAD®) for Localized Prostate Cancer.
    Flegar L; Baunacke M; Buerk BT; Proschmann R; Zacharis A; Propping S; Huber J; Thomas C; Borkowetz A
    Urol Int; 2022; 106(9):903-908. PubMed ID: 34814157
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The inhibition of ferrochelatase enhances 5-aminolevulinic acid-based photodynamic action for prostate cancer.
    Fukuhara H; Inoue K; Kurabayashi A; Furihata M; Fujita H; Utsumi K; Sasaki J; Shuin T
    Photodiagnosis Photodyn Ther; 2013 Dec; 10(4):399-409. PubMed ID: 24284092
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Commentary on: Padeliporfin Vascular-targeted Photodynamic Therapy Versus Active Surveillance in Men With Low-risk Prostate Cancer (CLIN1001 PCM301): An Open-label, Phase 3, Randomized Controlled Trial.
    Johnston J; Struss WJ; Black PC
    Urology; 2017 Jun; 104():7-8. PubMed ID: 28342930
    [No Abstract]   [Full Text] [Related]  

  • 54. Development of a functionalized UV-emitting nanocomposite for the treatment of cancer using indirect photodynamic therapy.
    Sengar P; Juárez P; Verdugo-Meza A; Arellano DL; Jain A; Chauhan K; Hirata GA; Fournier PGJ
    J Nanobiotechnology; 2018 Feb; 16(1):19. PubMed ID: 29482561
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison between endothelial and tumor cells in the response to verteporfin-photodynamic therapy and a PI3K pathway inhibitor.
    Fateye B; Wan A; Yang X; Myers K; Chen B
    Photodiagnosis Photodyn Ther; 2015 Mar; 12(1):19-26. PubMed ID: 25636781
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatment planning and dose analysis for interstitial photodynamic therapy of prostate cancer.
    Davidson SR; Weersink RA; Haider MA; Gertner MR; Bogaards A; Giewercer D; Scherz A; Sherar MD; Elhilali M; Chin JL; Trachtenberg J; Wilson BC
    Phys Med Biol; 2009 Apr; 54(8):2293-313. PubMed ID: 19305043
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Vascular-targeted photodynamic therapy in the treatment of neovascular age-related macular degeneration: Clinical perspectives.
    Kawczyk-Krupka A; Bugaj AM; Potempa M; Wasilewska K; Latos W; Sieroń A
    Photodiagnosis Photodyn Ther; 2015 Jun; 12(2):161-75. PubMed ID: 25843911
    [TBL] [Abstract][Full Text] [Related]  

  • 58. WST11, a novel water-soluble bacteriochlorophyll derivative; cellular uptake, pharmacokinetics, biodistribution and vascular-targeted photodynamic activity using melanoma tumors as a model.
    Mazor O; Brandis A; Plaks V; Neumark E; Rosenbach-Belkin V; Salomon Y; Scherz A
    Photochem Photobiol; 2005; 81(2):342-51. PubMed ID: 15623318
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Treatment of peritoneal carcinomatosis with photodynamic therapy: Systematic review of current evidence.
    Almerie MQ; Gossedge G; Wright KE; Jayne DG
    Photodiagnosis Photodyn Ther; 2017 Dec; 20():276-286. PubMed ID: 29111390
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Photodynamic therapy using pheophorbide and 670nm LEDs exhibits anti-cancer effects in-vitro in androgen dependent prostate cancer.
    Gheewala T; Skwor T; Munirathinam G
    Photodiagnosis Photodyn Ther; 2018 Mar; 21():130-137. PubMed ID: 29102652
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.